Biogen Inc. BIIB submitted an unsolicited bid to accumulate the entire excellent shares of Sage Therapeutics Inc. SAGE that it doesn’t already owned by Biogen for $7.22 per share.
Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, contemplating the monetary success of the Zurzuvae launch for postpartum melancholy (PPD).
Biogen says Zurzuvae exceeded its expectations.
Additionally Learn: Biogen Downgraded On Pipeline Setbacks And Leqembi Gross sales Slowdown
Goldman Sachs estimates Zurzuvae might attain international peak gross sales of roughly $700 million for PPD by 2034.
Richter notes that traders stay targeted on Biogen’s development methods. This contains increasing its pipeline, pursuing exterior enterprise improvement, or leveraging new alternatives to counter declining income within the latter half of the last decade.
Throughout the third quarter earnings name, administration highlighted the potential for an $8 billion to $10 billion deal throughout the subsequent two years, primarily specializing in uncommon illnesses and immunology.
Additionally they emphasised continued curiosity in neurology whereas acknowledging the power of Biogen’s immunology capabilities from its a number of sclerosis franchise and the necessity to diversify additional.
William Blair has persistently seen Zurzuvae’s function in treating postpartum melancholy as much less important to Biogen’s general worth. As a substitute, the agency prioritizes the progress of Biogen’s late-stage packages and enhancements in Leqembi’s remedy profile.
Analyst Myles Minter means that whereas the deal could not enhance Biogen’s inventory, it supplies a sensible technique for advertising and marketing Zurzuvae and maximizing its worth.
If the deal is finalized, Biogen ought to take into account buying extra firms within the neuropsychiatry discipline to strengthen its collaboration with Zurzuvae, Minter says.
Value Motion: Biogen inventory is up 0.34% at $150.32 finally test Monday.
Learn Subsequent:
Picture: Shutterstock
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
